Please login to the form below

Increasing the speed of knowledge sharing in blood cancer to improve patient care

Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities. However, this makes keeping up-to-date with rapidly developing news, science, emerging data and evolving treatment approaches is challenging for today’s time poor haemato-oncologist, let alone knowledge hungry patients searching to keep abreast of potential new therapies.

Our own April congress journey started on the 3rd April in Valencia at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), followed by the International Society of Hematology XXXVI World Congress in Congress (ISH), which was hosted by the British Society for Haematology at the 56th Annual Scientific Meeting, between 18th-21st April.

The latter half of the month is focused on Myeloma, as this week we head across the Atlantic to Boston, USA and Myeloma 2016 and then back to Europe for Controversies in Multiple Myeloma (CoMy) on the 28th April.
This is an exciting and rewarding time to be working in blood cancer, with rapid clinical advances developing in to additional therapeutic options patients.  However, the compact April congress calendar highlights the significant volume of new information being presented and the difficulties haemato-oncologists and patients have finding, digesting and interpreting this information.

One solution to information access and overload is provided via short-form video with latest news, interviews, debates and presentations delivered by medical (KOLs) and patient (POLs) opinion leaders hosted on video channels. Independent open access publishers such as The Video Journal of Hematology (VJHemOnc) and Patient Advisory Channels such as provide short, digestible educational video for haemato-oncologists and cancer patients respectively, which can be accessed via the web or mobile devices.

For cancer professionals who can’t attend every conference, they can now watch conference highlights 24/7 and bring themselves up to date very quickly post congress. For patients they often seek to improve knowledge about their disease and potential treatment options to be better informed prior to a consultation. We know that patients prefer independent video content as a source of information with 20.9% having learned something from Patient Power, which led to a dialogue with their doctor and led to a change in your treatment plan*. That is a compelling reason to utilise video content at the heart of your medical education and patient-engagement strategy.

We travel the world to create and share engaging content, designed to meet the needs of today’s time-poor physicians who need rapid access to digestible, accessible digital content, and patients, who need access to trust-worthy and reliable information online.

If you would like to discover how we can leverage our network of relationships and understanding of healthcare brands and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact 
Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.

The original article can be found on the Brandcast Health

*Patient Power Survey, January 2016, N = 1,248

10th May 2016



Company Details

Brandcast Health

+44 (0)20 7291 5070

Contact Website

16-17 Little Portland Street

Latest content on this profile

Day 2 Round-up from the Giant Health Event
Robin gives a quick overview of day 2 of the Giant Health Event.
Brandcast Health
Why patient education is important in oncology
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Brandcast Health
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
Brandcast Health
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
Brandcast Health
FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.
Brandcast Health
Overview of the GIANT Health Event
Shafi Ahmed, PhD, FRCS, Director of Virtual Medics and Medical and GIANT Event Co-chair, provides an overview of the GIANT Health Event.
Brandcast Health